First look: how kidneys affect new drug
NCT ID NCT07348237
Summary
This early-stage study aims to understand how a new drug called MK-2828 is processed by the body in people with impaired kidney function. Researchers will compare blood levels of the drug in 24 participants—some with kidney disease and some healthy—after they receive one or two doses. The goal is to see if kidney problems change how the drug behaves, which is crucial for determining safe dosing for future patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Floridian Clinical Research ( Site 0001)
RECRUITINGMiami Lakes, Florida, 33016, United States
Contact Phone: •••-•••-••••
-
Orlando Clinical Research Center ( Site 0002)
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
-
Panax Clinical Research ( Site 0003)
RECRUITINGMiami Lakes, Florida, 33014, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.